Beaumont Financial Advisors LLC Has $1.43 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Beaumont Financial Advisors LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 3.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,616 shares of the company’s stock after buying an additional 572 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,429,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC lifted its holdings in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC lifted its stake in Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd acquired a new stake in Novo Nordisk A/S in the third quarter valued at approximately $98,765,000. Marshall Wace LLP grew its stake in shares of Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after buying an additional 689,441 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Novo Nordisk A/S during the third quarter worth $42,017,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.9 %

NYSE NVO opened at $80.95 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $97.15 and a 200 day simple moving average of $116.47. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The firm has a market capitalization of $363.25 billion, a P/E ratio of 26.20, a PEG ratio of 0.84 and a beta of 0.45.

Analyst Ratings Changes

Several research analysts have recently issued reports on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.